Cart
×
Avidity’s trial for individuals with Duchenne amenable to skipping exon 45 is aiming to start in the first half of 2027
Read Avidity’s Community Letter:
Entrada shares updates on Duchenne programs, including initiation of Cohort 2 in UK and EU trial skipping exon 45
As an early funder of Entrada Therapeutics, we are pleased to share their latest newsletter to the Duchenne community. This update includes news that after review of all the data […]
Servier’s Acquisition of Edgewise’s Sevasemten Marks Major Milestone for Becker and Duchenne Muscular Dystrophy Communities
The neuromuscular disease community received encouraging news this week as Edgewise Therapeutics announced the sale of sevasemten and its Becker and Duchenne muscular dystrophy programs to Servier, a global pharmaceutical company with […]
Dyne submits Biologics License Application (BLA) to the FDA for Exon 51-skipping z-rostudirsen
CureDuchenne was an early funder of Dyne Therapeutics, which today announced they have submitted a BLA to the FDA for z-rostudirsen, for the treatment of individuals with Duchenne amenable to […]
CureDuchenne Announces Partnership with Tevard Biosciences to Advance Suppressor tRNA Therapy for the Treatment of Duchenne Muscular Dystrophy
Tevard Biosciences to present most recent data to Duchenne community for first time at CureDuchenne FUTURES National Conference on May 22 with webinar to follow on May 28 Newport Beach, […]
Dyne initiates global Phase 3 trial in Duchenne amenable to skipping exon 51, ahead of planned FDA submission for accelerated approval in the US
Dyne Therapeutics, which received early funding from CureDuchenne, is initiating a Phase 3 FORZETTO Trial of z-rostudirsen in individuals with Duchenne amenable to skipping exon 51. Dyne is on track […]
RegenXBio announces positive topline results from pivotal Phase 3 microdystrophin gene therapy trial
RegenXBio shared positive topline results from their pivotal Phase 3 AFFINITY DUCHENNE study of RGX-202 in 31 individuals with Duchenne aged 1 year and older. The study met the primary […]
First Participant Dosed in Phase 3 Trial for SGT-003 in Duchenne
Solid Biosciences has announced the first participant has been dosed in the Phase 3 IMPACT DUCHENNE trial evaluating SGT-003. The global study is now underway, with active sites in Australia […]
Entrada Therapeutics announced positive initial data from their Phase 1/2 ELEVATE-44-201 study in DMD patients amenable to skipping exon 44.
Entrada Therapeutics, who received early funding from CureDuchenne to advance their Endosomal Escape Vehicle Platform, today announced positive initial data from their Phase 1/2 ELEVATE-44-201 study in DMD patients amenable […]